⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292035 | 0.92 | — | — | |
| SCHEMBL292224 | 0.83 | — | — | |
| SCHEMBL292303 | 0.77 | — | — | |
| SCHEMBL2120204 | 0.76 | — | — | |
| SCHEMBL2699774 | 0.74 | — | — | |
| SCHEMBL3933845 | 0.74 | — | — | |
| SCHEMBL18338964 | 0.73 | KDM4E (0.32) | — | |
| SCHEMBL11573275 | 0.73 | — | — | |
| SCHEMBL8588368 | 0.73 | RAB9A (0.38) | — | |
| SCHEMBL9206429 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827257-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-11-28 | — | — | US | disclosed |
| US-9750759-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-09-05 | — | — | US | disclosed |
| EP-2597091-B1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-9187445-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2015-11-17 | — | — | US | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| EP-2231633-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-10-30 | — | — | EP | disclosed |
| EP-2597091-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2013-05-29 | — | — | EP | disclosed |
| US-20120270934-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20110034549-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2011-02-10 | — | — | US | disclosed |
| WO-2011003058-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| US-20100256240-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2231590-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| US-20100184862-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090325976-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2120554-A1 | PROSTACYCLIN DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008079383-A1 | PROSTACYCLIN DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-03 | — | — | WO | disclosed |